Digestive Disease Interventions 2019; 03(01): 052-062
DOI: 10.1055/s-0037-1608806
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

TACE, DEE-TACE, and Its Evolution in Metastatic Disease

Luke Byers
1   Department of Radiology, Division of Vascular and Interventional Radiology, University of Colorado, Denver, Colorado
,
Matthew A. Brown
1   Department of Radiology, Division of Vascular and Interventional Radiology, University of Colorado, Denver, Colorado
,
D. T. Johnson
1   Department of Radiology, Division of Vascular and Interventional Radiology, University of Colorado, Denver, Colorado
,
Paul J. Rochon
1   Department of Radiology, Division of Vascular and Interventional Radiology, University of Colorado, Denver, Colorado
› Author Affiliations
Further Information

Publication History

05 October 2017

26 October 2017

Publication Date:
24 January 2019 (online)

Abstract

Intra-arterial hepatic therapy is a relatively new technique popularized in the 1990s and 2000s and is built on decades of incremental development and discovery. Intra-arterial oncologic embolization therapy broadly includes transarterial embolization, transarterial chemoembolization (TACE), drug-eluting embolic transarterial chemoembolization, and transarterial radioembolization. These therapies have been included in the multidisciplinary treatment algorithm of hepatocellular carcinoma (HCC) and metastatic disease. Barcelona Clinic for Liver Cancer treatment guidelines specifically recommends TACE for the treatment of intermediate stage HCC. Research and clinical practice have seen extension of intra-arterial therapy to also broadly include unresectable HCC in many circumstances including palliation and a bridge to transplant. Some evidence also suggests an expanding role for intra-arterial therapy in the context of other primary liver neoplasms as well as metastatic disease with general considerations carrying over from the experience of treating HCC. In general, the efficacy of these treatments is similar, and selection of therapy is based on physician expertise and preference.

 
  • References

  • 1 Dandy WE. Ventriculography following the injection of air into the cerebral ventricles. Ann Surg 1918; 68 (01) 5-11
  • 2 Sicard JAFJ. Methode generale d'exploration radiologique par l'huile iode'e (Lipiodol). Bull Soc Med Hop Paris 1922; 46: 463-468
  • 3 Graham EA, Cole WH. Roentgenologic examination of the gallbladder: Preliminary report of a new method utilizing the intravenous injection of tetrabromophenolphthalein. J Am Med Assoc 1983; 250 (21) 2975-2976
  • 4 Cole WH. The development of cholecystography: the first fifty years. Am J Surg 1978; 136 (05) 541-560
  • 5 dos Santos R, Lamas A. Pereira-Caldas J Artériographie des membres et l'aorte et des ses branches abdominales. Bull. et mém. Soc. nat. de chir. 1929; 55: 585
  • 6 Wilkins RH, Moniz E. Arterial Encephalography, Its Importance in the Localization of Cerebral Tumors. J Neurosurg 1964; 21 (02) 144-156
  • 7 Hamby WB, Gardner W. Treatment of pulsating exophthalmos: with report of two cases. Arch Surg 1933; 27 (04) 676-685
  • 8 Vitek JJ, Smith MJ. The myth of the Brooks method of embolization: a brief history of the endovascular treatment of carotid-cavernous sinus fistula. J Neurointerv Surg 2009; 1 (02) 108-111
  • 9 Bierman HR, Byron Jr RL, Kelley KH, Grady A. Studies on the blood supply of tumors in man. III. Vascular patterns of the liver by hepatic arteriography in vivo. J Natl Cancer Inst 1951; 12 (01) 107-131
  • 10 Seldinger SI. Catheter replacement of the needle in percutaneous arteriography; a new technique. Acta Radiol 1953; 39 (05) 368-376
  • 11 Bierman HR, Byron Jr RL, Miller ER, Shimkin MB. Effects of intra-arterial administration of nitrogen mustard. Am J Med 1950; 8 (04) 535
  • 12 Klopp CT, Alford TC, Bateman J, Berry GN, Winship T. Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report. Ann Surg 1950; 132 (04) 811-832
  • 13 Sullivan RD, Miller E, Sikes MP. Antimetabolite-metabolite combination cancer chemotherapy. Effects of intraarterial methotrexate-intramuscular Citrovorum factor therapy in human cancer. Cancer 1959; 12 (06) 1248-1262
  • 14 Lucas RJ, Tumacder O, Wilson GS. Hepatic artery occlusion following hepatic artery catheterization. Ann Surg 1971; 173 (02) 238-243
  • 15 Ansfield FJ, Ramirez G, Skibba JL, Bryan GT, Davis Jr HL, Wirtanen GW. Intrahepatic arterial infusion with 5-fluorouracil. Cancer 1971; 28 (05) 1147-1151
  • 16 Ariel IM. Radioactive isotopes for adjuvant cancer therapy: animal experimentation and preliminary results in human application. Arch Surg 1964; 89 (02) 244-249
  • 17 Blanchard RJ, Lafave JW, Kim YS, Frye CS, Ritchie WP, Perry Jr JF. Treatment of patients with advanced cancer utilizing Y90 microspheres. Cancer 1965; 18 (03) 375-380
  • 18 Goldstein HM, Wallace S, Anderson JH, Bree RL, Gianturco C. Transcatheter occlusion of abdominal tumors. Radiology 1976; 120 (03) 539-545
  • 19 Almgård LE, Fernström I, Haverling M, Ljungqvist A. Treatment of renal adenocarcinoma by embolic occlusion of the renal circulation. Br J Urol 1973; 45 (05) 474-479
  • 20 Doyon D, Mouzon A, Jourde AM, Regensberg C, Frileux C. [Hepatic, arterial embolization in patients with malignant liver tumours (author's transl)]. Ann Radiol (Paris) 1974; 17 (06) 593-603
  • 21 Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148 (02) 397-401
  • 22 Kato T, Nemoto R, Mori H, Takahashi M, Harada M. Arterial chemoembolization with mitomycin C microcapsules in the treatment of primary or secondary carcinoma of the kidney, liver, bone and intrapelvic organs. Cancer 1981; 48 (03) 674-680
  • 23 Fortner JG, Mulcare RJ, Solis A, Watson RC, Golbey RB. Treatment of primary and secondary liver cancer by hepatic artery ligation and infusion chemotherapy. Ann Surg 1973; 178 (02) 162-172
  • 24 Matsui O, Kadoya M, Yoshikawa J. , et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993; 188 (01) 79-83
  • 25 Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994; 35 (10) 1637-1644
  • 26 Shepherd FA, Rotstein LE, Houle S, Yip TC, Paul K, Sniderman KW. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 1992; 70 (09) 2250-2254
  • 27 Dancey JE, Shepherd FA, Paul K. , et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000; 41 (10) 1673-1681
  • 28 Adachi E, Matsumata T, Nishizaki T, Hashimoto H, Tsuneyoshi M, Sugimachi K. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. Cancer 1993; 72 (12) 3593-3598
  • 29 Madden MV, Krige JE, Bailey S. , et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993; 34 (11) 1598-1600
  • 30 Bruix J, Llovet JM, Castells A. , et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27 (06) 1578-1583
  • 31 Yamada R, Kishi K, Sato M. , et al. Transcatheter arterial chemoembolization (TACE) in the treatment of unresectable liver cancer. World J Surg 1995; 19 (06) 795-800
  • 32 Llovet JM, Real MI, Montaña X. , et al; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359 (9319): 1734-1739
  • 33 Lo CM, Ngan H, Tso WK. , et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35 (05) 1164-1171
  • 34 Cammà C, Schepis F, Orlando A. , et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224 (01) 47-54
  • 35 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37 (02) 429-442
  • 36 BTG. TheraSphere Package Insert. https://www.btg-im.com/getattachment/TheraSphere/Products/Indications/TheraSphere-Package-Insert_USA_Rev-14.pdf.aspx , 2017 . Accessed October 4, 2017
  • 37 Humanitarian Device Exemption FDA. MDS NORDION THERASPHERE YTTRIUM-90 GLASS MICROSPHERES. 1999 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfhde/hde.cfm?id=H980006 . Accessed October 4, 2017
  • 38 SIRTeX. SIR-Spheres Microspheres Package Insert. https://www.sirtex.com/media/155127/pi-ec-12.pdf . Accessed October 4, 2017
  • 39 Premarket Approval FDA. SIR-SPHERES. 2002 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P990065 . Accessed October 4, 2017
  • 40 Lewis AL, Gonzalez MV, Lloyd AW. , et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006; 17 (2 Pt 1): 335-342
  • 41 Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85
  • 42 Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60 (08) 646-649
  • 43 Kamath PS, Wiesner RH, Malinchoc M. , et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33 (02) 464-470
  • 44 Wiesner R, Edwards E, Freeman R. , et al; United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124 (01) 91-96
  • 45 Okuda K, Ohtsuki T, Obata H. , et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56 (04) 918-928
  • 46 Oken MM, Creech RH, Tormey DC. , et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (06) 649-655
  • 47 Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19 (03) 329-338
  • 48 Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30 (01) 61-74
  • 49 Mazzaferro V, Regalia E, Doci R. , et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699
  • 50 Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013; 266 (02) 376-382
  • 51 Network OPaT. Organ Procurement and Transplantation Network Policy. 2017 https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf#nameddest=Policy_09 . Accessed August 7, 2017
  • 52 Network UNfOS-OPaT. OPTN/UNOS Policy Notice Changes to HCC Criteria for Auto Approval. 2016 ; 12/2016: https://optn.transplant.hrsa.gov/media/2027/liver_policynotice_201612.pdf . Accessed August 7, 2017
  • 53 Pinter M, Hucke F, Graziadei I. , et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 2012; 263 (02) 590-599
  • 54 Ray Jr CE, Brown AC, Green TJ. , et al. Survival outcomes in patients with advanced hepatocellular carcinoma treated with drug-eluting bead chemoembolization. AJR Am J Roentgenol 2015; 204 (02) 440-447
  • 55 Lewandowski RJ, Kulik LM, Riaz A. , et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9 (08) 1920-1928
  • 56 Salem R, Gordon AC, Mouli S. , et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology 2016; 151 (06) 1155-1163.e2
  • 57 Brown KT, Do RK, Gonen M. , et al. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol 2016; 34 (17) 2046-2053
  • 58 Gade TPF, Tucker E, Nakazawa MS. , et al. Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma. Radiology 2017; 283 (03) 702-710
  • 59 Shimizu S, Takehara T, Hikita H. , et al. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer 2012; 131 (03) 548-557
  • 60 Raoul JL, Sangro B, Forner A. , et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37 (03) 212-220
  • 61 Brown DB, Nikolic B, Covey AM. , et al; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2012; 23 (03) 287-294
  • 62 Garwood ER, Fidelman N, Hoch SE, Kerlan Jr RK, Yao FY. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. Liver Transpl 2013; 19 (02) 164-173
  • 63 Niu Z-J, Ma Y-L, Kang P. , et al. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol 2012; 29 (04) 2992-2997
  • 64 Luo J, Guo R-P, Lai ECH. , et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011; 18 (02) 413-420
  • 65 Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol 2013; 13: 60
  • 66 Tan JC, Coburn NG, Baxter NN, Kiss A, Law CH. Surgical management of intrahepatic cholangiocarcinoma--a population-based study. Ann Surg Oncol 2008; 15 (02) 600-608
  • 67 Benson A, D'Angelica MI, Abrams T. , et al. NCCN Clinical Practice Guidelines in Oncology Hepatobiliary Cancers Version 2.2016. 2016; https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf , 2017 . Accessed August 7, 2017
  • 68 Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 2015; 41 (01) 120-127
  • 69 Ray Jr CE, Edwards A, Smith MT. , et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2013; 24 (08) 1218-1226
  • 70 Boehm LM, Jayakrishnan TT, Miura JT. , et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol 2015; 111 (02) 213-220
  • 71 Hendlisz A, Van den Eynde M, Peeters M. , et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28 (23) 3687-3694
  • 72 Van Cutsem E, Cervantes A, Adam R. , et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27 (08) 1386-1422
  • 73 van Hazel GA, Heinemann V, Sharma NK. , et al. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 2016; 34 (15) 1723-1731
  • 74 Fiorentini G, Aliberti C, Tilli M. , et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32 (04) 1387-1395
  • 75 Barbier CE, Garske-Román U, Sandström M, Nyman R, Granberg D. Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 2016; 43 (08) 1425-1431
  • 76 Padia SA, Lewandowski RJ, Johnson GE. , et al; Society of Interventional Radiology Standards of Practice Committee. Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. J Vasc Interv Radiol 2017; 28 (01) 1-15
  • 77 Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P. ; NET-Liver-Metastases Consensus Conference. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB 2015; 17 (01) 29-37
  • 78 Kitano M, Davidson GW, Shirley LA. , et al. Transarterial Chemoembolization for Metastatic Neuroendocrine Tumors With Massive Hepatic Tumor Burden: Is the Benefit Worth the Risk?. Ann Surg Oncol 2016; 23 (12) 4008-4015
  • 79 Chen JX, Rose S, White SB. , et al. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival. Cardiovasc Intervent Radiol 2017; 40 (01) 69-80
  • 80 Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol 2017; 101 (01) 38-44
  • 81 Klingenstein A, Haug AR, Zech CJ, Schaller UC. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Intervent Radiol 2013; 36 (01) 158-165
  • 82 Gonsalves CF, Eschelman DJ, Thornburg B, Frangos A, Sato T. Uveal Melanoma Metastatic to the Liver: Chemoembolization With 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea. AJR Am J Roentgenol 2015; 205 (02) 429-433
  • 83 Valsecchi ME, Terai M, Eschelman DJ. , et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J Vasc Interv Radiol 2015; 26 (04) 523-32.e2
  • 84 Valpione S, Aliberti C, Parrozzani R. , et al. A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments. Melanoma Res 2015; 25 (02) 164-168
  • 85 Fiorentini G, Aliberti C, Del Conte A. , et al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo 2009; 23 (01) 131-137
  • 86 Carling U, Dorenberg EJ, Haugvik SP. , et al. Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications. Cardiovasc Intervent Radiol 2015; 38 (06) 1532-1541
  • 87 Venturini M, Pilla L, Agostini G. , et al. Transarterial chemoembolization with drug-eluting beads preloaded with irinotecan as a first-line approach in uveal melanoma liver metastases: tumor response and predictive value of diffusion-weighted MR imaging in five patients. J Vasc Interv Radiol 2012; 23 (07) 937-941
  • 88 Vogl TJ, Naguib NN, Nour-Eldin NE, Eichler K, Zangos S, Gruber-Rouh T. Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. Eur Radiol 2010; 20 (01) 173-180
  • 89 Vogl TJ, Kreutzträger M, Gruber-Rouh T. , et al. Neoadjuvant TACE before laser induced thermotherapy (LITT) in the treatment of non-colorectal non-breast cancer liver metastases: feasibility and survival rates. Eur J Radiol 2014; 83 (10) 1804-1810
  • 90 Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12 (03) 321-326
  • 91 Facciorusso A, Bellanti F, Villani R. , et al. Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials. United European Gastroenterol J 2017; 5 (04) 511-518
  • 92 Lammer J, Malagari K, Vogl T. , et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (01) 41-52
  • 93 Lee EW, Alanis L, Cho S-K, Saab S. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. Korean J Radiol 2016; 17 (04) 472-488